0.71
Schlusskurs vom Vortag:
$0.7658
Offen:
$0.7695
24-Stunden-Volumen:
715.40K
Relative Volume:
0.41
Marktkapitalisierung:
$60.07M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-35.50
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
+8.23%
1M Leistung:
+15.43%
6M Leistung:
-31.07%
1J Leistung:
-55.62%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
0.71 | 60.07M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
2021-11-15 | Eingeleitet | BTIG Research | Buy |
2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
2021-03-29 | Eingeleitet | JP Morgan | Overweight |
2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
2020-03-04 | Eingeleitet | Barclays | Equal Weight |
2019-11-20 | Eingeleitet | Guggenheim | Buy |
2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
2019-06-13 | Eingeleitet | Mizuho | Buy |
2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-03-11 | Eingeleitet | Barclays | Overweight |
2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
2018-10-15 | Eingeleitet | Goldman | Neutral |
2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
2018-06-01 | Eingeleitet | SunTrust | Buy |
2018-01-05 | Eingeleitet | Citigroup | Buy |
2017-09-08 | Eingeleitet | Wedbush | Outperform |
2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
2017-03-02 | Eingeleitet | Instinet | Buy |
2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect - Zacks Investment Research
Should investors be concerned about CytomX Therapeutics Inc (CTMX)? - uspostnews.com
CytomX Therapeutics Inc (CTMX)’s Market Momentum: Closing Strong at 0.73, Down -0.80 - DWinneX
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
CytomX Therapeutics (NASDAQ:CTMX) Now Covered by Piper Sandler - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler sets CytomX stock target at $2.50, rates Overweight By Investing.com - Investing.com Canada
CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus
Piper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX) - The Globe and Mail
Piper Sandler sets CytomX stock target at $2.50, rates Overweight - Investing.com
New Outlook On CytomX Therapeutics Inc - stocksregister.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by Prudential Financial Inc. - Defense World
CytomX Therapeutics Inc (NASDAQ: CTMX) 5.47% Incline Turns Investors Away - stocksregister.com
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive - simplywall.st
CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World
Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX
CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World
StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com India
CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada
Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India
CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada
CytomX Therapeutics CEO sells $22,555 in stock - Investing.com India
CytomX Therapeutics Executives Sell Shares for Tax Obligations - TradingView
CytomX therapeutics general counsel sells $6,111 in stock By Investing.com - Investing.com UK
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Australia
CytomX at Barclays Healthcare: Probody Platform Progress By Investing.com - Investing.com South Africa
CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World
What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - stocksregister.com
CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):